Although both statins and PPARγ agonists are available and commonly used, clinical trials will be needed to determine the relative safety and potential efficacy of these pharmacotherapies in patients with autoimmune PAP. Here, PPARG is linked to autoimmune pulmonary alveolar proteinosis.